Last updated: February 27, 2026
What is NDC 16571-0679?
NDC 16571-0679 corresponds to [Drug Name], a prescription medication approved for [indication]. The drug is manufactured by [Manufacturer] and received FDA approval on [date]. It is available in [dosage forms and strengths].
Market Overview
Therapeutic Area and Competition
[Drug Name] operates within the [therapeutic class], competing with drugs such as [competitors]. The market size for this segment is estimated at $[value] billion in 2022, with a compound annual growth rate (CAGR) of [value]% projected until 2027.
Market Drivers
- Rising prevalence of [disease/condition].
- Increasing adoption of [treatment modality].
- Recent FDA label updates expanding indications into [new areas].
- Growing healthcare coverage and insurance reimbursement for [drug class].
Regulatory Milestones
- FDA approval date: [date].
- Patent expiry: [date].
- Expected biosimilar or generic entries: [dates].
Current Pricing Landscape
Price Points
- Wholesale acquisition cost (WAC): $[value] per [unit/strength].
- Average wholesale price (AWP): $[value].
- Reimbursement rates: Vary by payer, with average reimbursement at $[value] per prescription.
Price Comparisons
| Drug |
WAC per unit |
Indication |
Approved date |
Market share (%) |
| [Drug Name] |
$[value] |
[indication] |
[date] |
[percentage] |
| Competitor A |
$[value] |
[indication] |
[date] |
[percentage] |
| Competitor B |
$[value] |
[indication] |
[date] |
[percentage] |
Pricing Trends
The price of [drug name] has remained stable since approval, with recent adjustments tied to changes in supply chain costs and payer negotiations. Historically, prices for similar drugs in this class have decreased [percentage]% within the first three years after patent expiry.
Market Projections
Revenue Forecasts
Based on current market penetration, sales growth, and formulary acceptance, revenue projections are as follows:
| Year |
Projected Sales (USD millions) |
CAGR (%) |
Notes |
| 2023 |
$[value] |
-- |
Initial launch phase |
| 2024 |
$[value] |
[value]% |
Increased market adoption |
| 2025 |
$[value] |
[value]% |
Entry of generics expected, potential price erosion |
Price Decline Expectations
- Patent expiration scheduled for [date].
- Entry of biosimilars or generics expected within [timeframe].
- Price erosion of [percentage]% over five years post-patency.
Competitive Risks
- Price reductions driven by biosimilar entry.
- Payer pressure to use lower-cost alternatives.
- Regulatory changes affecting labeling or indication expansion.
Key Factors Affecting Future Pricing
- Market penetration and acceptance rates.
- Patent and exclusivity status.
- Manufacturing costs.
- Regulatory decisions on indication and label updates.
- Healthcare policy and reimbursement landscape.
Conclusion
[Drug Name] has a stable market position with moderate growth potential before patent expiry. The entry of biosimilars or generics around [date] is likely to reduce prices by [percentage]% over the subsequent five years. Price projections should account for competitive pressures, payer negotiations, and regulatory developments.
Key Takeaways
- NDC 16571-0679 is positioned within a growing therapeutic area with expanding indications.
- Current prices are around $[value] WAC per unit, with stable pricing trends.
- Market projections suggest sales will grow at a CAGR of [value]% until 2025, with significant price erosion post-patent expiry.
- The entry of biosimilars or generics will be the primary price mitigation factor.
- Payer dynamics and regulatory decisions will influence future prices.
FAQs
Q1: When is patent expiration for NDC 16571-0679?
Patent expiry is scheduled for [date], after which biosimilar or generic competition is expected.
Q2: What are the primary competitors?
Main competitors include [competitors], with similar indications and comparable efficacy.
Q3: How does the current pricing compare to similar drugs?
Current WAC pricing is $[value] per unit, comparable to other drugs in the [therapeutic class].
Q4: What factors could impact price reductions?
Patent expiry, biosimilar entry, payer negotiations, regulatory label updates.
Q5: What is the potential revenue decline after biosimilar entry?
Revenues could decline by [percentage]%, or more, within five years of biosimilar approval.
References
- [1] Food and Drug Administration (FDA). (2023). Drug Approvals and Regulatory Changes.
- [2] IMS Health. (2022). Market Share and Pricing Trends in [Therapeutic Area].
- [3] EvaluatePharma. (2022). Global Oncology Market Forecasts.
- [4] Medicare.gov. (2023). Part B and Part D Pricing and Reimbursement Data.
- [5] U.S. Patent and Trademark Office. (2022). Patent Expiry Dates in Biologic Sectors.
